This systemic review of the literature and meta-analysis aimed to evaluate the current state of the evidence for and against reimplantation of the aortic valve (RAV) versus the composite valve graft (CVG) intervention in patients with Marfan syndrome. Random effects metaregression was performed across the study arms with logit-transformed proportions of in-hospital deaths as an outcome measure when possible. Results are presented as odds ratios with 95% confidence intervals (CIs) and P-values. Other outcomes are summarized with medians, interquartile ranges (IQR) and ranges and the numbers of patients at risk. Twenty retrospective studies that included a combined 2156 patients with long-term follow-up were identified for analysis after a literature search. The in-hospital mortality rate favoured the RAV procedure with an odds ratio of 0.23 [95% CI 0.09-0.55, P = 0.001]. The survival rate at mid-term for the RAV cohort was 96.7% (CI 94.2-98.5) vs. 86.4% ) for the CVG group and 93.1% (CI 66.4-100) for the RAV group vs. 82.6% (CI 74.9-89.2) for the CVG group for the long term. Freedom from valve-related reintervention (median percentages) for the long term was 97.6% (CI 90.3-100%) for the RAV procedure and 88.6% (CI 79.1-95.5) for a CVG. This systematic review of the literature stresses the advantages of the RAV procedure in patients with Marfan syndrome in regard to long-and short-term results as the treatment of choice in aortic root surgery. The RAV procedure reduces in-hospital as well as long-term deaths and protects against aortic valve reintervention.
INTRODUCTION
Marfan syndrome is a systematic hereditary autosomal dominant illness of connective tissue, caused by a gene mutation that is responsible for encoding fibrilin-1 [1] . An aneurysm of the aortic root, ascending aorta and acute Type A dissection are the most frequent reasons for deaths of patients with Marfan syndrome [2] . Recent guidelines delineate an aggressive surgical approach for repair and replacement of the diseased aortic root [3] ; however, the choice of surgical modality is at the discretion of the surgeon. Currently, 2 surgical approaches are recognized as state-of-the-art treatments for aortic root aneurysm.
Composite graft implantation (CVG) was first described by Bentall and De Bono [4] and has been considered the treatment of choice for a long period, with excellent outcomes in long-term follow-up [5, 6] . However, in this relatively young population, the implementation of a mechanical prosthesis exposes patients to the cumulative risk of lifelong anticoagulation, restricted haemodynamics and elevated risk for thromboembolism. In comparison, a biological valve has better haemodynamic performance and does not require life-long anticoagulation therapy. A major disadvantage is the structural deterioration of the valve that results in dysfunction and the need for a new intervention [7, 8] . Many patients with Marfan syndrome have structurally normal aortic valve leaflets that may not need replacement, which makes an aortic valve reimplantation respectively. David procedure an attractive option [9, 10] . Although there is evidence of excellent results following reimplantation of the aortic valve (RAV) technique, many surgeons refrain from using this surgical alternative because the reconstructive procedure is technically demanding. Consequently, excellent long-term outcomes may be achieved only in highly specialized centres. Further, the incidence of aortic valve failure in the long term is another factor that is not explored in detail in the literature. There is currently no high level of evidence in favour of or about the disadvantages of these 2 procedures. The aim of this systematic review of all available evidence on the CVG and RAV procedures was to improve insight into the long-term follow-up and contribute to a better †These authors contributed equally to this work. understanding of outcomes following surgical intervention in patients with Marfan syndrome.
METHODS
This systematic review follows the recommendation of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (Fig. 1 ) on conducting systematic reviews of randomized controlled trials [11] .
Quality assessment
The internal validity of each study was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) Methodology checklist for randomized controlled trials by the 2 reviewers independently (S.M. and D.S.) [12] .
Quality was rated as follows: 'High (+ +)' denoted that most of the criteria were fulfilled. If they were not fulfilled, the conclusions of the study were unlikely to change. 'Moderate (+)' denoted that some criteria were fulfilled. Criteria not adequately described were unlikely to alter the conclusions. 'Low (-)' denoted that few or no criteria were fulfilled. In this case, the conclusions were likely to change. As recommended by the Scottish Intercollegiate Guidelines Network, studies rated by both reviewers as low quality were excluded from further analysis.
Search strategy
A search of the Cochrane, PubMed, Scopus, Web of Science and EMBASE databases was conducted using the following terms: (aortic root replacement AND aortic root reconstruction) OR (Bentall procedure AND David procedure) OR (composite graft AND aortic root reimplantation) OR (Marfan syndrome AND aortic root aneurysm) and was limited to publications from 1967 to 2017. In addition, the entire Cochrane library was researched for titles, abstracts or key words of publications. Manuscripts written in English, German and French were considered. Two reviewers (S.M. and D.S.) screened the titles and abstracts of the identified studies. A third independent reviewer (D.B.) assessed whether the inclusion and exclusion processes were performed correctly. In case of disagreement, an agreement was negotiated. References of selected articles were cross-checked for other relevant studies. Authors were contacted when a publication could not be obtained or not all required information could be retrieved from the publication.
Inclusion/exclusion criteria
Experimental reports, in vitro studies, editorials, letters, case reports, reports evaluating patients only on acute Type A dissections or aortic rupture and reports of other clinical results were not included. The review process considered reports in adults, reports on mortality/survival and/or morbidity after a CVG or RAV procedure, minimal duration of follow-up > _5 years, completeness of follow-up = 90% (high quality) and study size n > _ 30, reflecting the centre's experience. Reports with mixed populations were considered if at least > _40% of the cohort had Marfan syndrome. In the case of multiple publications on the same patient cohort, the most recent publication was included in the analysis.
Data extraction
Microsoft Excel and Review Manager version 4.2 for Windows (The Cochrane Collaboration, 2003) were used for data extraction, and R for Windows was used for statistical analyses [13] . To control for potential heterogeneity caused by procedure, publications were allocated to the following categories: (i) series on CVG and composite graft, respectively; (ii) series on RAV and aortic reimplantation, respectively. Study design was documented in each paper that reported the inclusion criteria. Data with regard to authorship, date of publication, cohort quantity (sample size, gender, age), Marfan population size, study design, follow-up duration and the defined end point were extracted. Outcome events were registered according to the 2008 American Association for Thoracic Surgery/Society of Thoracic Surgeons/European Association for Cardio-Thoracic Surgery guidelines [14] . 
Primary and secondary end points
Primary end points were defined as in-hospital deaths, mortality/ survival during the follow-up period and reoperation related to aortic root and aortic valve diseases, respectively. Secondary end-points were reoperation rate because of bleeding, stroke rate, thromboembolism and pacemaker implantation during the hospital stay. Further, we included as secondary end-points during the follow-up period the incidence of valve insufficiency > _2, endocarditis and stroke rate.
Statistical analysis
Descriptive statistics were used to summarize baseline characteristics of the patients across studies. Outcome variables included mortality/survival and freedom from reoperation in 3 different time intervals: in-hospital deaths (defined as death within 30 days after surgery), mortality/survival and freedom from reoperation after 5 years (mid-term follow-up) and 10 or more years (longterm follow-up). A random effects metaregression was performed across study arms using either surgical technique with logittransformed proportions of in-hospital deaths as an outcome measure [15] . A metaregression model was fitted to in-hospital deaths including percentage of patients with Marfan syndrome and with mention of Type A dissection as well as year of publication. The year of publication, the percentage of patients with Marfan syndrome and the percentage of patients with indications of a Type A dissection in each study were assumed to confound the effect of the surgical technique on in-hospital deaths. We therefore addressed these 3 confounders within the random effects meta-analytic model. The estimated effect of surgical technique on in-hospital deaths was adjusted for year of publication later or equal to 2010 and the percentage of patients with Marfan syndrome equal to 100%. Mean age was strongly negatively correlated with percentage of patients with Marfan syndrome; therefore, we did not include mean age as a confounder in the models. Results are presented as proportions ratios with the RAV procedure compared to the CVG procedure, including 95% confidence intervals (CIs) and P-values. Random effects models were used for pooling primary outcomes addressing survival and freedom from reoperation after 5 years and > _10 years.
Secondary outcomes were reported less exhaustively in the original publications. Therefore, they were summarized with descriptive statistics including ranges, interquartile ranges and medians reported for the RAV procedure and the CVG procedure separately. Again, random effects models were used for pooling if more than 2 studies reported the respective numbers. The baseline number of patients was used as the denominator for all calculations.
RESULTS
According to the defined search terms, 1342 reports were identified as eligible for analysis. Of these, 232 abstracts were chosen for a final reading. A total of 183 reports were excluded for the following reasons: no differentiation between the CVG and RAV procedures (n = 40), double publication (n = 5), case report (n = 14), surgical technique (n = 5), follow-up not completed (n = 10), studies under-defined the cutoff (n = 92) and other (n = 43) (Fig. 1) .
Finally, 20 retrospective studies with a combined 2156 patients published between 1991 and 2016 met the defined inclusion criteria.
The SIGN checklist was used to assess risk of bias within studies. No study was excluded from the meta-analysis. The study quality was good in all of the reports (Supplementary Material, Table S1 ). The overall mean percentage of patients with Marfan syndrome was 78.1%. A total of 22 study arms were identified, 11 dealing with the CVG procedure and 11 with the RAV procedure. Median patient number per study arm was 67 [interquartile range (IQR) 44-146] for CVG and 59 (IQR 52-108) for the RAV procedure. Table 1 provides an overview of publications considered for analysis. Two reports compared both surgical procedures, with n = 103 patients in the CVG and n = 98 patients in the RAV group, 9 series evaluated the outcome only of the CVG procedure (n = 1037 patients) and 9 reports reported only the RAV procedure (n = 873 patients) ( Table 1 ).
In detail, 12 studies with n = 183 patients at risk reported survival with a follow-up period of 10 years or more, 2 studies reported the RAV procedure with n = 39 patients at risk and 10 studies (with n = 380, 144 patients at risk), the CVG procedure. Freedom from aortic valve-related reintervention in the long term was reported in 8 reports: 6 were on the CVG procedure (n = 112 patients at risk) and 2, on the RAV procedure (n = 37 patients at risk).
Descriptive statistics are presented in Table 2 , including intraoperative data as well as the indications for the interventions. The most frequent indication for intervention was dilatation of the aortic root: for the RAV procedure at 91.1% (IQR 82. (Table 2) .
In-hospital deaths determined by the random effects model favoured the RAV procedure at 0.3% [CI 0-0.8] vs. 3.4% (CI 1.8-5.5) in the composite graft pool. This result was similar to that with the metaregression model, whereby 20 studies were included in the metaregression addressing in-hospital death as an outcome. The estimated odds ratio of the RAV versus the CVG procedure was 0.23 (95% CI 0.09-0.55, P = 0.001) in favour of the RAV procedure (Figs 2 and 3 ).
In the mid-term as well in the long-term follow-up, the evaluated survival rate favoured the RAV procedure. The survival rate was 96.7% (CI 94.2-98.5) vs. 86.4% (CI 82.8-89.6) in the mid-term and 93.1% (CI 66.4-100) vs. 82.6% (CI 74.9-89.2) in the long term, respectively. Pooled freedom from valve-related reintervention was similar at mid-term in both procedures: 97.0% (CI 90.7-99.9) for RAV and 92.6% (CI 84.8-97.8) for CVG. However, for the long term, the freedom from valve-related reintervention was 97.6% (CI 90.3-100) in favour of the RAV procedure vs. 88.6% (CI 79.1-95.5) for the CVG procedure ( Table 3) .
The pooled in-hospital reoperation rate was 4.1% (CI 2.9-5.4) less frequent with the RAV compared to 7.8% (CI 5.0-11.2) with the CVG procedure. The incidence of neurological events was 1.4% (CI 0.5-2.6) for RAV vs. 1.4% (CI 0.2-3.8) for CVG.
Implantation of a permanent pacemaker was 1.8% (CI 0.7-3.4) in RAV vs. 4.4% (CI 0-15.4) in CVG ( Table 3) .
The pooled incidence of stroke rate during the follow-up period for the RAV procedure was 0% (CI 0-0.6%) vs. 4.4% (CI 0-15.4) for CVG. The incidence of thromboembolic events was 0% (CI 0-0.4) for RAV and 9.7% (CI 5.3-15.4) for the CVG cohort. The endocarditis rate was lower in RAV with 0.7% (CI 0-2.8) vs. 3.6% (CI 1.8-5.9) in CVG. The rate of aortic valve insufficiency > _2 was 5.0% (CI 0. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in the RAV cohort (Table 4) .
DISCUSSION
This systematic review presented the largest meta-analysis on patients with Marfan syndrome with aortic root disease published to date, evaluating the outcome of the 2 most frequently used surgical approaches: the composite graft and the aortic valve reimplantation procedure. Aortic valve reimplantation is established and well accepted in the surgical community as a surgical alternative for patients with aortic root dilatation and an intact valve. Theoretically, the procedure provides clear longterm benefits over the composite graft, such as freedom from prosthetic valve-related thromboembolic events, adverse events related to oral anticoagulation and incidence of structural valve deterioration. Thus, one would suppose that valve reimplantation is the gold standard in young patients with dilatative aortic root disease. However, although the procedure was first described about 30 years ago by David et al. [36, 37] , the proportion of patients undergoing the reconstructive intervention in the United States is still less than 15% and is not increasing [38] . The reasons that individual surgeons or even institutions refrain from performing aortic valve reimplantation may be due, on the one hand, to the technical complexity of the procedure and, on the other hand, to a lack of comparative data and information on short-and long-term results.
The main finding of our analysis was that aortic root reimplantation is clearly associated with improved in-hospital and midand long-term survival rates compared to those associated with a composite graft. In-hospital survival was superior despite the longer cross-clamp time, longer extracorporeal circulation duration and longer circulatory arrest time (Fig. 1) . Evaluating the mortality rate in both intervention modalities, in function of time of intervention, the aortic root reimplantaion was constantly represented by superior outcome (Fig. 2) .
The higher in-hospital mortality rate associated with the composite graft cannot be explained by population diversity, and in both groups the ages and the male/female ratio were similar. It is important to note that female gender has been identified as a predictive factor for in-hospital death of patients having aortic valve replacement (64). The elevated mortality rate in our analysis may in part be explained by the fact that some of the patients were sicker. The ratio of advanced congestive heart failure [New York Heart Association (NYHA) >II] and severe aortic valve insufficiency was higher in the composite graft group. Additionally, the rate of permanent pacemaker implantation as well the incidence of early reoperation for bleeding was higher in the CVG cohort. The literature on long-term survival analysing the outcome of both surgical interventions is limited. There were only a handful [19, 28] of manuscripts included that compared both surgical techniques with long-term follow-up in a single population. In both reports, the hospital mortality rate was not significantly different between the 2 groups [19, 28] . However, detailed reasons for the perioperative mortality rate were reported only by Karck et al. [28] , who attributed the main reasons for in-hospital deaths in the composite graft group to low cardiac output, sepsis and stroke. In the follow-up period, most patients died of cardiac reasons or of a thromboembolic event [19, 28] . Secondly, when considering the valve-related reintervention rate, one could suggest better valve durability in the composite graft group, especially in a mechanical composite graft with lifelong durability. In our pooled cohort, more than 90% of the patients had a mechanical device. The short-term freedom from valve-related reintervention rate was similar for both surgical groups. This result correlates with the findings of the 2 largest retrospective studies in which the incidence of valve-related reintervention at 5 years in a mechanical composite graft versus a valve-sparing procedure was not significantly different [19, 30] . Over the long term, the valve-sparing procedure has a clear advantage, with freedom from valve-related reintervention of over 90%. It seems that the native aortic valve, even in a synthetic aortic root, without natural compliant sinuses of Valsalva, has superior durability compared to the aortic valve prosthesis. These results require further discussion, because the reports with longterm results on valve reimplantation report freedom from valve-related reintervention greater than 95% at 20 years. Such excellent results were described in only 3 included manuscripts and are from the same research group [30, 36, 37] . This fact emphasizes that only a few centres in Western countries have adapted the reimplantation technique as a routine intervention. In comparison, the composite graft was the subject of a diverse offering of studies with different staff from different centres [15, 16, 24, 26] and consequently presented much more diverse results.
The stroke rate is, not surprisingly, very low in the valve-sparing population. This fact was reported in 3 studies [19, 27, 32] ; in all cases, the incidence of a neurological event was zero. The same was true for the incidence of thromboembolic events, which was zero in the valve-sparing group in most of the reports. The same may be said for the incidence of thromboembolic events, which was higher in the composite graft subgroup by a factor of 9.
Limitations
Publication bias may have been present in this meta-analysis because of the small number of studies comparing CVG versus RAV in parallel; we were not able to use funnel plots that typically address this problem. Further, this paper is a systematic analysis of observational studies, all of which are retrospective. Consequently, the limitations of a meta-analysis and of pooling retrospectively collected data apply to our report [39] . Additionally, the included data are heterogeneous because no study evaluates one or the other surgical approach in the isolated Marfan population.
CONCLUSIONS
In patients with Marfan syndrome with dilatation of the aortic root and aortic valve incompetence, the main goal of the intervention was to prevent aortic dissection and to restore aortic valve function. The composite graft technique is a routine procedure in most cardiosurgical centres worldwide and has satisfactory short-and mid-term mortality rates. Shedding light on the impact of artificial valves and oral anticoagulation-related long-term adverse effects shows that the composite graft technique has a clear disadvantage compared to the valve-sparing procedure. The main drawback is allied to the valve prosthesis. A mechanical prosthesis is associated with a considerable number of late thromboembolic events [38, 40] , whereas the biological prosthesis in a young population has a relatively high incidence of structural valve deterioration and consecutive reinterventions. The relatively high reoperation rate for a biological prosthesis over the long term should be weighed against the oral anticoagulated-related risk from a mechanical prosthesis [41] .
An alternative aortic root reconstructive procedure should be considered, especially because the valve reimplantation technique has excellent outcomes and should therefore gain more acceptance in the cardiosurgical community.
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